<DOC>
	<DOCNO>NCT02482857</DOCNO>
	<brief_summary>This single-center , open-label , randomize control trial . Patients stable angina pectoris without use dual antiplatelet therapy anticoagulation therapy schedule coronary artery bypass grafting ( CABG ) Karolinska University Hospital Stockholm , Sweden eligible . This study investigate patient undergone CABG whether increase dose frequency acetylsalicylic acid ( ASA ) treatment improve efficacy ASA regard platelet inhibition compare standard dose cardiovascular prevention ( 75 mg daily ) first three month surgery . Patients randomly assign postoperative ASA dose 75mg daily , 75mg twice daily 160 mg daily . The study dose ASA start hospital discharge continue three month . Blood sample serum thromboxane B2 ( TxB2 ) analyse take surgery , discharge , one three month . All available data collect prospectively . Informed consent obtain patient meet inclusion criterion initiation study-specific procedure .</brief_summary>
	<brief_title>Optimal Dose Acetylsalicylic Acid After Coronary Artery Bypass Grafting</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Stable coronary artery disease ≥18 year age Scheduled undergo elective CABG surgery Willing participate able provide inform consent Intake drug ASA know influence platelet function , include nonsteroidal antiinflammatory drug ( NSAIDs , include COX2 selective antiinflammatory drug ) , GPIIbIIIa inhibitor , clopidogrel , dipyridamole , warfarin acenocoumarol within 7 day enrolment Hemorrhagic diathesis know platelet dysfunction Chronic renal failure require dialysis Platelet count outside 100 000 450 000/μL range Haemoglobin &lt; 8g/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>